Objective To explore the impact of Ganjikang Formula（肝积康方） on the five-year survival rate in hepatitis B-related primary liver cancer（PLC） patients of healthy Qi deficiency and blood stasis pattern and to analyze the associated impact factors. Methods Eighty patients who were diagnosed as hepatitis B-related PLC for the first time and received adjuvant therapy of Ganjikang Formula in Henan Province Hospital of Traditional Chinese Me-dicine from January 2010 to September 2014 were included as Chinese medicine group; one hundred and sixty hepatitis B-related PLC patients who did not take Ganjikang Formula were matched to the Chinese medicine group by age and sex at a ratio of 1 ∶2. The survival time was assessed; the demographic characteristics and relevant clinical information were collected. The COX regression analysis was used to screen out the protective factors for survival of the patients. Survival analyses were conducted in different subgroups in terms of liver cancer type（BCLC stage: 0-B stage vs. CD stage）

treatment method（routine medical treatment vs. minimally invasive treatment vs. resection treatment） and hepatitis B virus e antigen（HbeAg） type（HBeAg-positive vs. HBeAg-negative）. Results The median survival time of the Chinese medicine group was 28.58 months

and the five-year survival rate was 35.00%; the median survival time of the control group was 9.95 months

and the five-year survival rate was 8.80%; the difference between the two groups was statistically significant（P<0.01）. The adjuvant treatment of Ganjikang Formula was a protective factor for the survival of hepatitis B-related PLC（HR=0.416

95% confidence interval 0.295 to 0.586）. Further subgroup analysis in terms of different liver cancer types showed that Ganjikang Formula was a protective factor for all subgroups

and the differences between subgroups were statistically significant（P<0.05）. The subgroup analysis in terms of different treatment course showed that the longer treatment of Ganjikang Formula was associated with longer survival time（P<0.01）. Conclusion Ganjikang Formula is a protective factor associated with the survival of patients with hepatitis B-related PLC

and the treatment time is positively correlated with the survival time.